| Yin, Jun |
CA209-6KP, NCT05213312: Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC |
|
|
| Recruiting | 2/3 | 90 | RoW | Nivolumab, Cisplatin, Paclitaxel, 5Fluorouracil, Esophagectomy (minimally invasive) | Shanghai Zhongshan Hospital, Bristol-Myers Squibb | Esophageal Squamous Cell Carcinoma | 11/22 | 03/24 | | |
| Recruiting | 2 | 30 | RoW | PD-L1 Antibody SHR-1316, PD-L1 antibody | Shanghai Zhongshan Hospital | Oesophageal Squamous Cell Carcinoma | 07/22 | 12/22 | | |
NCT05420480: Two-field Versus Three-field Lymph Node Dissection in ESCC After Neoadjuvant Therapy |
|
|
| Not yet recruiting | N/A | 323 | RoW | Two-Field lymph node dissection, Three-Field lymph node dissection | Shanghai Zhongshan Hospital, Baoji Central Hospital, Sixth Affiliated Hospital, Sun Yat-sen University, Suining Central Hospital, Jieyang People's Hospital, Second Affiliated Hospital of Nantong University, Taixing People's Hospital, Hebei Medical University Fourth Hospital, Suzhou Municipal Hospital, Fujian Provincial Hospital, Shandong Jining No.1 People's Hospital, The General Hospital of Western Theater Command, Zhejiang Cancer Hospital, Shanghai Chest Hospital | Esophageal Squamous Cell Carcinoma | 06/24 | 06/27 | | |
| Zhou, Jian |
NCT05063071: Tenofovir Alafenamide for HBV Prophylaxis in Post Orthotopic Liver Transplant |
|
|
| Active, not recruiting | 4 | 150 | RoW | Tenofovir Alafenamide 25 MG | Fudan University | HBV, POST LIVER TRANSPLANT | 07/22 | 12/22 | | |
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis | TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Neovascular Age-related Macular Degeneration | 09/24 | 02/25 | | |
ALTN-AK105-III-02, NCT04344158: A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) |
|
|
| Active, not recruiting | 3 | 648 | RoW | AK105 Injection, Anlotinib Hydrochloride Capsules, Sorafenib Tosylate Tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Hepatocellular Carcinoma (HCC) | 12/26 | 12/26 | | |
NCT06507436: The Phase III Clinical Study of Herombopag for the Treatment of Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery |
|
|
| Recruiting | 3 | 101 | RoW | Herombopag tablets, Herombopag placebo tablets | Jiangsu HengRui Medicine Co., Ltd. | Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery | 08/25 | 09/25 | | |
NCT06591520: AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer |
|
|
| Not yet recruiting | 3 | 682 | RoW | AK112, Gemcitabine, Cisplatin, Durvalumab, Gemcitabine, Cisplatin | Akeso | Biliary Tract Cancer | 07/27 | 12/27 | | |
TQ05105-III-01, NCT06682169: Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease |
|
|
| Recruiting | 3 | 182 | RoW | Rovadicitinib, Imatinib, Methotrexate, Mycophenolate mofetil, Rituximab | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Graft-versus-host Disease | 10/29 | 12/30 | | |
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin |
|
|
| Active, not recruiting | 3 | 1576 | Japan, US, RoW | Orforglipron, LY3502970, Semaglutide | Eli Lilly and Company | Type 2 Diabetes | 09/25 | 09/25 | | |
NCT05342194: Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study |
|
|
| Not yet recruiting | 3 | 480 | RoW | Toripalimab, Tuoyi, Lenvatinib mesylate capsules, LENVIMA, Placebo IV, Toripalimab placebo, Oral placebo, Lenvatinib mesylate capsules placebo, Oxaliplatin for injection, Gemcitabine hydrochloride, Cisplatin | Shanghai Junshi Bioscience Co., Ltd. | Intrahepatic Cholangiocarcinoma | 05/27 | 05/27 | | |
NCT04521153: Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma |
|
|
| Active, not recruiting | 2/3 | 294 | RoW | Camrelizumab, Apatinib Mesylate, TACE treatment, Radical surgery | Shanghai Zhongshan Hospital | Hepatocellular Carcinoma, Immunotherapy, Molecular Targeted Therapy | 07/25 | 03/26 | | |
zs-ICC-2019, NCT03951597: Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and PD1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma |
|
|
| Active, not recruiting | 2 | 30 | RoW | combined therapy using oxaliplatin and gemcitabine chemotherapy, Lenvatinib and PD1 antibody (JS001) | Shanghai Zhongshan Hospital | Cholangiocarcinoma, Intrahepatic | 01/20 | 11/21 | | |
zs-ICC-2020, NCT04361331: Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma |
|
|
| Active, not recruiting | 2 | 60 | RoW | Lenvatinib combined with gemox, gemox chemotherapy, Toripalimab combined with lenvatinib | Shanghai Zhongshan Hospital | Cholangiocarcinoma, Intrahepatic | 09/21 | 12/21 | | |
NCT04961788: Anti-PD1 Antibody Toripalimab Combined With Gemox as First-line Therapy in Late-stage Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 30 | RoW | Gemox combimed PD1 antibody | Shanghai Zhongshan Hospital | Intrahepatic Cholangiocarcinoma | 12/21 | 12/22 | | |
NCT04850157: Tislelizumab Combined With IMRT Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT |
|
|
| Not yet recruiting | 2 | 30 | RoW | Tislelizumab, IMRT | Shanghai Zhongshan Hospital | Hepatocellular Carcinoma With Portal Vein Tumor Thrombus | 04/22 | 12/23 | | |
NCT04295317: PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After Surgery |
|
|
| Active, not recruiting | 2 | 65 | RoW | PD-1 blocking antibody SHR-1210, Capecitabine | Shanghai Zhongshan Hospital | Intrahepatic Cholangiocarcinoma | 06/25 | 06/25 | | |
NCT05262959: A Single Center Study of Donafenib Combined With PD-1 + TACE in the First-line Treatment of aHCC |
|
|
| Completed | 2 | 30 | RoW | Donafenib, PD-1, TACE | Shanghai Zhongshan Hospital | Donafenib | 04/24 | 05/24 | | |
NCT06530784: Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 2 | 36 | RoW | Cryoablation, PD-1 antibody and bevacizumab | Shanghai Zhongshan Hospital | Carcinoma, Hepatocellular | 12/25 | 05/26 | | |
NCT06737081: SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies |
|
|
| Recruiting | 2 | 60 | RoW | SAL-0951 tablets 4mg, SAL-0951 tablets 4mg group, SAL-0951 tablets 5mg, SAL-0951 tablets 5mg group | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Anemia | 12/25 | 06/26 | | |
NCT06778031: A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer |
|
|
| Not yet recruiting | 2 | 54 | RoW | SHR-A1811, SHR-1316, SHR-8068 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer | 06/28 | 09/28 | | |
| Recruiting | 1/2 | 30 | RoW | Toripalimab, Sorafenib | Shanghai Zhongshan Hospital | Hepatocellular Carcinoma | 10/21 | 12/21 | | |
NCT05652920: Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC |
|
|
| Recruiting | 1/2 | 105 | RoW | Ori-C101 | OriCell Therapeutics Co., Ltd. | Hepatocellular Carcinoma | 12/26 | 12/26 | | |
NCT05627063: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 169 | US, RoW | ABSK121-NX | Abbisko Therapeutics Co, Ltd | Solid Tumor | 03/25 | 06/25 | | |
BIATICH, NCT05593380: The Effect of BIA Monitoring of Brain Edema on the Neurological Prognosis of Supratentorial Massive ICH |
|
|
| Recruiting | N/A | 190 | RoW | Parenchymal Intracranial pressure monitor, Integra Life Sciences Camino Intracranial Monitor, Treatment based on clinical and imaging observations | Xiangya Hospital of Central South University | Cerebral Hemorrhage, Hypertensive, Intracranial Hypertension, Monitoring, Critical Care, Treatment Outcome, Invasive Intracranial Pressure Monitoring, Large-volume Cerebral Hemorrhage | 12/24 | 03/25 | | |
NCT06178809: Clinical Research on Dynamic Monitoring MRD Via Plasma ctDNA After Systemic Therapy of Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 475 | RoW | | Singlera Genomics Inc., Shanghai Zhongshan Hospital | Hepatocellular Carcinoma | 04/25 | 12/25 | | |
NCT05200221: A Single Center Real-world Study of Donafenib in the Treatment of Hepatocellular Carcinoma in Routine Clinical Practice |
|
|
| Recruiting | N/A | 300 | RoW | | Shanghai Zhongshan Hospital | Donafenib, Hepatocellular Carcinoma | 01/24 | 03/24 | | |
NCT05941286: Effect of Continuous Glucose Monitoring System Alerts on Diabetes Management in the Hospital |
|
|
| Recruiting | N/A | 527 | RoW | CGM system with both glucose predictive alerts and threshold alerts on, CGM system with only glucose threshold alerts on, CGM system with glucose alerts off | Shanghai 6th People's Hospital | Diabetes Mellitus | 08/25 | 09/25 | | |
NCT06023147: A Real-world Study of the Short-term Efficacy and Safety of E-TACE in Patients With Hepatocellular Carcinoma (HCC) |
|
|
| Not yet recruiting | N/A | 298 | RoW | E-TACE | Xuhua Duan | Hepatocellular Carcinoma | 09/24 | 09/25 | | |
NCT06591286: Effects of Real-time Continuous Glucose Monitoring System on Hospital-to-home Transitional Blood Glucose Control |
|
|
| Recruiting | N/A | 150 | RoW | RT-CGM, SMBG | Shanghai 6th People's Hospital | Diabetes Mellitus, Type 2 | 03/26 | 09/27 | | |
NCT06662630: Physiological Effects and Safety of Continuous High-frequency Oscillatory Ventilation in Mechanical Ventilation Patients |
|
|
| Recruiting | N/A | 30 | RoW | High-Frequency Oscillatory Ventilation | Shanghai Zhongshan Hospital | Atelectasis, Acute Respiratory Distress Syndrome, VAP - Ventilator Associated Pneumonia | 10/25 | 10/26 | | |
NCT05087459: Treatment of Avatrombopag for Thrombocytopenia in Patients Undergoing Selective Resection of Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 141 | RoW | Avatrombopag, Doptelet | Shanghai Zhongshan Hospital | Thrombocytopenia | 06/22 | 07/22 | | |
NCT05431621: Establishment of Molecular Classification Models for Early Diagnosis of Digestive System Cancers |
|
|
| Completed | N/A | 2430 | RoW | | Shanghai Zhongshan Hospital, Xuhui Central Hospital, Shanghai, Changhai Hospital, Hubei Cancer Hospital, Shanghai Public Health Clinical Center, Singlera Genomics Inc. | Esophageal Cancer, Gastric (Stomach) Cancer, Colorectal Cancer, Hepatocellular Carcinoma | 06/23 | 07/23 | | |
NCT05707585: Lung Cancer Diagnosis by Detecting Epigenetic Imprinting Alterations in Bronchoalveolar Lavage |
|
|
| Recruiting | N/A | 2064 | RoW | Quantitative Chromogenic Imprinted Gene in situ Hybridization (QCIGISH) | The Second Affiliated Hospital of Dalian Medical University, Fudan University, Zongda Hospital affiliated to Southeast University, West China Hospital, Henan Provincial People's Hospital, First Hospital of China Medical University, Shengjing Hospital, The First Affiliated Hospital of Guangzhou Medical University, Lisen Imprinting Diagnostics, Inc. | Lung Cancer | 01/24 | 07/24 | | |
| Ge, Junbo |
NCT03008083: Comparison Three vs Twelve Months of Dual Anti-Platelet Therapy After Stent Implantation |
|
|
| Recruiting | 4 | 2446 | RoW | 3 months DAPT, Ticagrelor (180 mg/day) or Clopidogrel (75 mg/day), 12 months DAPT | Shanghai MicroPort Medical (Group) Co., Ltd. | Drug-Eluting Stents, Percutaneous Coronary Intervention | 12/20 | 10/22 | | |
CLEAN, NCT04665648: Clinical Efficacy and sAfety of Intravenous Infusion of Nicorandil During Primary Percutaneous Coronary Intervention |
|
|
| Recruiting | 4 | 1500 | RoW | Nicorandil, intraveous nicorandil, Placebo, intraveous palcebo | Fudan University | ST Elevation Myocardial Infarction, Percutaneous Coronary Intervention | 08/24 | 12/24 | | |
NCT04135677: Clinical Outcomes Between Anticoagulation and DAPT Therapy in AF Patients Successfully Undergoing LAAO |
|
|
| Recruiting | 4 | 826 | RoW | Rivaroxaban, new oral anticoagulation, DAPT, dual antiplatelet therapy | Shanghai Zhongshan Hospital | Left Atrial Appendage Thrombosis, Thrombi, Stroke | 10/24 | 10/24 | | |
TIGER, NCT04255602: A Study of Low and Standard-dose Ticagrelor After Intervention for ACS Patients |
|
|
| Recruiting | 4 | 2120 | RoW | Ticagrelor 60mg, Ticagrelor 90mg | Shanghai Tong Ren Hospital, Shanghai Jiao Tong University School of Medicine, Fudan University | Acute Coronary Syndrome, Coronary Stent Implantation | 12/24 | 12/24 | | |
| Recruiting | 4 | 2500 | Europe, RoW | Pressure Microcatheter guided strategy - PIOS MC, Pressure Wire guided strategy - PIOS - PW, Pressure Microcatheter guided strategy - Standard of care, Pressure Wire guided strategy - Standard of care | CoreAalst BV, Insight Lifetech Co., Ltd. | Coronary Artery Disease, Acute Coronary Syndrome | 06/26 | 06/30 | | |
NCT05260411: A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With Hyperlipidemia |
|
|
| Recruiting | 3 | 240 | RoW | AK102, Placebo | Akeso | Hyperlipidemia | 06/22 | 12/22 | | |
RECOVERII, NCT04571580: Effect of Low-dose Intracoronary Reteplase on Myocardial Infarct Size During Primary Percutaneous Coronary Intervention |
|
|
| Terminated | 3 | 36 | RoW | Normal Saline, intracoronary normal saline, Reteplase Injection 9mg, intracoronary reteplase 9mg, Reteplase Injection 18mg, intracoronary reteplase 18mg | Ge Junbo | Acute ST-segment Elevation Myocardial Infarction | 01/23 | 01/23 | | |
| Active, not recruiting | 2 | 100 | RoW | Pirfenidone Oral Capsule, Placebo Oral Capsule | Shanghai Zhongshan Hospital, Beijing Continent Pharmaceutical Co, Ltd. | Myocardial Fibrosis | 05/24 | 06/24 | | |
NCT02698839: A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES) |
|
|
| Active, not recruiting | N/A | 539 | RoW | BuMA Supreme, BuMA™ | Sino Medical Sciences Technology Inc. | Coronary Artery Disease | 03/18 | 12/25 | | |
OPC, NCT02698852: A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES) |
|
|
| Active, not recruiting | N/A | 1000 | RoW | BuMA Supreme | Sino Medical Sciences Technology Inc. | Coronary Artery Disease | 05/19 | 12/25 | | |
NCT03466918: China S3: Safety and Effectiveness of Edwards Lifesciences SAPIEN 3 THV in the Chinese Population |
|
|
| Active, not recruiting | N/A | 58 | RoW | SAPIEN 3 THV with the Commander delivery system | Edwards Lifesciences | Aortic Stenosis, Symptomatic Aortic Stenosis, Aortic Regurgitation | 07/19 | 09/25 | | |
| Not yet recruiting | N/A | 616 | NA | intravascular ultrasound (IVUS), coronary angiography | Shanghai Zhongshan Hospital | Coronary Artery Disease, Left Main Coronary Artery Disease | 09/21 | 09/23 | | |
NCT04582877: Pressure Guidewire System Multi-center, Prospective, Self-Control, Clinical Trial |
|
|
| Completed | N/A | 300 | RoW | FFR measurement | Zurich Medical Inc. | Myocardial Ischemia | 11/23 | 04/24 | | |
NCT03716011: A Postmarket Clinical Trial for EXCROSSAL Stent in CAD Patients With 3-month DAPT or 12-month DAPT |
|
|
| Not yet recruiting | N/A | 2700 | RoW | EXCROSSAL | JW Medical Systems Ltd | Coronary Artery Disease | 12/21 | 12/25 | | |
NCT04414878: VitaFlowâ„¢ II Transcatheter Aortic Valve System Pre-market Trial |
|
|
| Recruiting | N/A | 145 | RoW | VitaFlowâ„¢ II Transcatheter Aortic Valve System | Shanghai MicroPort CardioFlow Medtech Co., Ltd. | Aortic Stenosis | 01/22 | 01/27 | | |
NCT04575012: Compare Early With Deferred Invasive Strategy for STEMI Presenting 24-48 Hours From Symptom Onset |
|
|
| Not yet recruiting | N/A | 1200 | NA | Deferred invasive strategy, Early invasive strategy | Shanghai Zhongshan Hospital | ST-segment Elevation Myocardial Infarction (STEMI) | 12/22 | 12/25 | | |
NCT05391191: Safety and Feasibility of TRISKELE in Severe AS |
|
|
| Recruiting | N/A | 7 | RoW | MitrAssist TRISKELE® transcatheter aortic valve system | Shanghai Zhongshan Hospital | Aortic Valve Disease | 03/23 | 03/23 | | |
| Recruiting | N/A | 30 | RoW | FreeFlow percutaneous atrial septal shunt | Shanghai Zhongshan Hospital | Pulmonary Arterial Hypertension | 09/27 | 09/27 | | |
| Recruiting | N/A | 2132 | RoW | caFFR, Coronary Angiography-Derived Fractional Flow Reserve, FFR, Fractional Flow Reserve | Peking University First Hospital, Rainmed Ltd., Suzhou, China | Coronary Artery Disease, Coronary Stenosis, Myocardial Ischaemia, Coronary Circulation, Stable Angina Pectoris, Unstable Angina Pectoris, Asymptomatic Ischemia, Acute Myocardial Infarction, Percutaneous Coronary Intervention | 12/23 | 12/25 | | |
NCT03714802: Modified T-Stenting With Szabo Technique Versus T-Stenting for Bifurcation Lesions in Coronary Heart Diseases |
|
|
| Recruiting | N/A | 100 | RoW | Szabo T-Stenting Technique, T-Stenting Technique | Shanghai Zhongshan Hospital | Coronary Artery Disease | 12/23 | 12/24 | | |
| Recruiting | N/A | 200 | RoW | Oral apixaban | Shanghai Zhongshan Hospital | Evaluate the Safety and Efficacy of Apixaban | 12/23 | 12/24 | | |
NCT06110988: A Clinical Study for the Pan-vascular Interventional Robotic System |
|
|
| Not yet recruiting | N/A | 5 | RoW | Pan-vascular interventional robotic system | Shenzhen Institute of Advanced Biomedical Robot Co., Ltd. | Percutaneous Coronary Intervention, Pan-vascular Interventional Robotic System | 09/24 | 09/24 | | |
NCT06213714: The 5th Generation Tele-Robotic-Assisted Percutaneous Coronary Intervention: A First-in-Human Trial |
|
|
| Not yet recruiting | N/A | 12 | NA | 5G Tele-Robotic-Assisted PCI, VRS100 Robotic Console System | Yan'an Affiliated Hospital of Kunming Medical University, Shanghai Zhongshan Hospital, Kunming Chenggong District People's Hospital | Coronary Artery Disease, Myocardial Ischemia, Cardiovascular Diseases, Coronary Disease, Arteriosclerosis | 06/24 | 09/24 | | |
NCT03736226: A Post-Approval, Single-Arm Study of the SYNERGY Stent System in China |
|
|
| Active, not recruiting | N/A | 2000 | RoW | SYNERGYTM Stent System | Boston Scientific Corporation | Cardiovascular Diseases | 08/24 | 03/28 | | |
NCT06502938: A Clinical Trial Evaluating the Pan-vascular Interventional Robotic System for Panvascularization Interventional Surgery |
|
|
| Not yet recruiting | N/A | 159 | RoW | Pan-vascular interventional robotic system, Traditional artificial percutaneous coronary intervention | Shenzhen Institute of Advanced Biomedical Robot Co., Ltd. | Percutaneous Coronary Intervention | 07/25 | 12/25 | | |
NCT06101888: Safety and Effectiveness of TaurusTrio™ Heart Valve System in Patients With Severe Aortic Regurgitation (AR) |
|
|
| Recruiting | N/A | 116 | RoW | TaurusTrio™ Heart Valve System | Peijia Medical Technology (Suzhou) Co., Ltd. | Aortic Regurgitation | 07/24 | 07/29 | | |
NCT06032572: Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) |
|
|
| Not yet recruiting | N/A | 204 | RoW | VRS100 robotic-assisted PCI, Manual PCI | Shenzhen Raysight Intelligent Medical Technology Co., Ltd., Shanghai Zhongshan Hospital, West China Hospital, Shenzhen People's Hospital | Coronary Artery Disease, Cardiovascular Diseases, Coronary Disease, Myocardial Ischemia, Arteriosclerosis, Vascular Disease Occlusive | 08/24 | 08/24 | | |
| Not yet recruiting | N/A | 100 | RoW | computed tomography myocardial perfusion, Invasive Coronary Angiography | Shanghai Zhongshan Hospital | Non-ST Elevation Myocardial Infarction | 02/25 | 02/26 | | |
VITAL, NCT05813704: Coronary Crossing System in Patients With Coronary Chronic Total Occlusions |
|
|
| Recruiting | N/A | 156 | RoW | Coronary Crossing System of Shanghai MicroPort Rhythm | Shanghai MicroPort Rhythm MedTech Co., Ltd., Shanghai Zhongshan Hospital, Xiamen Cardiovascular Hospital, Xiamen University, Shanghai Baoshan District Wusong Central Hospital, Wuhan Union Hospital, China, The First Affiliated Hospital of Nanchang University, First Affiliated Hospital Xi'an Jiaotong University, First Affiliated Hospital of Wenzhou Medical University, Tianjin First Central Hospital, The Affiliated Hospital Of Southwest Medical University, Hebei General Hospital, West China Hospital, First Affiliated Hospital of Army Medical University, PLA, Lanzhou University First Hospital, Nanfang Hospital, Southern Medical University, The Second Affiliated Hospital of Dalian Medical University, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Chronic Total Occlusion of Coronary Artery | 04/25 | 05/25 | | |
CONFIDENT, NCT05857904: Clinical Outcomes of CT-FFR Versus QFR-guided Strategy for Decision-Making in Patients With Stable Chest Pain |
|
|
| Not yet recruiting | N/A | 4648 | RoW | CT-FFR, QFR | Shanghai Zhongshan Hospital | Angina, Stable, Coronary Artery Disease | 05/25 | 05/28 | | |
NCT05947448: Efficacy and Safety of Mexartan Potassium Tablets (AZL-M) and Calcium Channel Blockers (CCB) in the Treatment of Adults With Essential Hypertension in Chinese Population: a National Multicenter, Prospective, Observational Study |
|
|
| Recruiting | N/A | 1215 | RoW | Azilsartan Medoxomil Potassium Tablet, Nifedipine Sustained -release Tablets, Levoamlodipine Maleate Table | Hasten Biopharmaceutical Co., Ltd. | Essential Hypertension | 06/25 | 12/25 | | |
| Recruiting | N/A | 5000 | RoW | Coronary CT angiography | Shanghai Zhongshan Hospital | Coronary Artery Disease | 12/25 | 12/30 | | |
NCT05194423: THE TRAVEL II TRIAL: Transcatheter Right Atrial-ventricular Valve rEplacement With LuX-Valve Via Jugular Vein |
|
|
| Recruiting | N/A | 150 | RoW | Tricuspid Valve Replacement System via jugular vein | Changhai Hospital, Shanghai Zhongshan Hospital, Fu Wai Hospital, Beijing, China, Beijing Anzhen Hospital, Wuhan Union Hospital, China, West China Hospital, Xijing Hospital, Guangdong Provincial People's Hospital, Second Affiliated Hospital, School of Medicine, Zhejiang University | Tricuspid Valve Regurgitation | 03/27 | 03/27 | | |
| Recruiting | N/A | 10000 | RoW | | Seung-Jung Park, CardioVascular Research Foundation, Korea | Coronary Artery Disease | 12/32 | 12/33 | | |
| Not yet recruiting | N/A | 271 | RoW | Angiography-drived Index of Microcirculatory Resistance, Angio-IMR, CaIMR | Shanghai Zhongshan Hospital, Shanghai 10th People's Hospital | Coronary Microvascular Dysfunction, Myocardial Ischemia | 05/21 | 10/21 | | |
CHART-OPTIMIZE, NCT05125107: PrOgnostic imPlicaTIons of 2-diMensIonal Patterns for Residual Disease After Stenting CharacteriZEd by Quantitative Flow Ratio Pullback Curve Analysis |
|
|
| Not yet recruiting | N/A | 1607 | NA | Quantitative Flow Ratio derived PPG and dQFR/ds | Shanghai Zhongshan Hospital, Chinese Academy of Medical Sciences, Fuwai Hospital | Coronary Artery Disease | 12/21 | 03/22 | | |
CHART-ORIGIN, NCT05104580: PrOgnostic Implications of PRe-stent Pullback Pressure GradIent and Post-stent Quantitative Flow Ratio in Patients UnderGoing Percutaneous Coronary INtervention |
|
|
| Not yet recruiting | N/A | 1395 | NA | Quantitative Flow Ratio derived PPG | Shanghai Zhongshan Hospital, Chinese Academy of Medical Sciences, Fuwai Hospital | Coronary Artery Disease | 01/22 | 03/22 | | |
| Recruiting | N/A | 378 | RoW | Coronary CTA | Shanghai Zhongshan Hospital | Coronary Artery Disease | 04/22 | 05/22 | | |
| Recruiting | N/A | 329 | RoW | Percutaneous coronary intervention | Shanghai Zhongshan Hospital | Coronary Artery Disease | 08/22 | 10/22 | | |
NCT04518826: A Comparison Between FFR Guided and CAG Guided Treatment Using DEB in ISR of DES |
|
|
| Not yet recruiting | N/A | 420 | NA | fractional flow reserve | Shanghai Zhongshan Hospital | In Stent Restenosis, Drug Eluting Stent, Coronary Artery Disease | 10/22 | 10/24 | | |
| Recruiting | N/A | 300 | RoW | CCTA and 18F-FDG-PET/CT | Shanghai Zhongshan Hospital | Coronary Artery Disease | 10/22 | 12/22 | | |
| Sun, Hui-Chuan |
NCT04994236: Hepatic Artery Infusion Chemotherapy for Unresectable Hepatocelluar Carcinoma Who Failed to Systemic Therapy |
|
|
| Recruiting | 2 | 49 | RoW | Hepatic artery infusion chemotherapy with FOLFOX regimens (oxaliplatin, fluorouracil, and leucovorin), HAIC | Hui-Chuan Sun | Hepatocellular Carcinoma | 08/22 | 12/22 | | |
NCT04639284: Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCC |
|
|
| Recruiting | N/A | 200 | RoW | Anti-angiogenic agents plus anti-PD-1/PD-L1 antibodies | Shanghai Zhongshan Hospital | Hepatocellular Carcinoma | 07/22 | 07/23 | | |
| Yuan, Wei Tang |
OPTIMA-6, NCT05410925: Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction |
|
|
| Recruiting | 4 | 2260 | RoW | Recombinant staphylokinase, Placebo | The First Affiliated Hospital with Nanjing Medical University | ST Elevation Myocardial Infarction | 12/26 | 12/27 | | |
NCT05472415: Effects of Cognicise and Arch Support Insoles in Older Adults With Mild Cognitive Impairment |
|
|
| Recruiting | N/A | 40 | RoW | cognicise, arch support insoles | National Taipei University of Nursing and Health Sciences | Mild Cognitive Impairment | 12/22 | 12/22 | | |
NCT05901480: An Investigator Initiated Study for OTOV101N+OTOV101C Injection |
|
|
| Recruiting | N/A | 25 | RoW | OTOV101N+OTOV101C Injections | Otovia Therapeutics | DFNB9 | 12/24 | 02/25 | | |
| Wang, Zheng |
NCT06387368: Clinical Study of Huaier Granule in the Treatment of Unresectable Pancreatic Cancer |
|
|
| Not yet recruiting | 4 | 488 | NA | Huaier Granule, Z20000109#NMPA Approval Number#, Capecitabine, Standard chemotherapy | Health Science Center of Xi'an Jiaotong University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology | Pancreatic Cancer Non-resectable | 03/28 | 08/28 | | |
NCT06368063: The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer |
|
|
| Recruiting | 4 | 642 | RoW | Huaier granule, Z20000109#NMPA Approval Number#, chemotherapy drugs, Standard chemotherapy | Health Science Center of Xi'an Jiaotong University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology | Pancreatic Cancer Resectable | 03/26 | 03/28 | | |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
NCT04521153: Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma |
|
|
| Active, not recruiting | 2/3 | 294 | RoW | Camrelizumab, Apatinib Mesylate, TACE treatment, Radical surgery | Shanghai Zhongshan Hospital | Hepatocellular Carcinoma, Immunotherapy, Molecular Targeted Therapy | 07/25 | 03/26 | | |
| Recruiting | 2 | 30 | RoW | Niraparib | Tianjin Huanhu Hospital | Recurrent Glioblastoma | 01/22 | 01/23 | | |
NCT04295317: PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After Surgery |
|
|
| Active, not recruiting | 2 | 65 | RoW | PD-1 blocking antibody SHR-1210, Capecitabine | Shanghai Zhongshan Hospital | Intrahepatic Cholangiocarcinoma | 06/25 | 06/25 | | |
NCT06569524: Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH) |
|
|
| Recruiting | 2 | 120 | RoW | TQA2225/AP025 or TQA2225/AP025 Placebo 25mg, TQA2225/AP025 or TQA2225/AP025 Placebo 50mg | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Non-alcoholic Steatohepatitis | 12/26 | 12/27 | | |
| Recruiting | 2 | 116 | RoW | Placebo, TQA3334 Tablet, Nucleoside (acid) analogs (NAs) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Hepatitis B | 12/25 | 06/26 | | |
NCT02802124: Carbon Ion Radiotherapy for the Treatment of Chinese Hepatocellular Carcinoma |
|
|
| Terminated | N/A | 30 | RoW | carbon-ion radiotherapy for tumor away from GI, carbon-ion radiotherapy for tumor adjacent to GI | Shanghai Proton and Heavy Ion Center | Hepatocellular Carcinoma | 10/23 | 10/23 | | |
NCT05229133: Efficacy and Safety of CLEAR in Myopia and Astigmatism in Chinese Population |
|
|
| Recruiting | N/A | 215 | RoW | CLEAR, Corneal lenticule extraction for advanced refractive correction | Ziemer Ophthalmic Systems AG, Tigermed Consulting Co., Ltd | Myopic Astigmatism | 03/23 | 03/23 | | |
NCT03573791: Biomarkers for Predicting Neoadjuvant Chemoradio-resistance for Middle-low Advanced Rectal Cancer |
|
|
| Recruiting | N/A | 152 | RoW | | Wuhan Union Hospital, China | Rectal Cancer, Cancer of Rectum, Cancer of the Rectum, Neoplasms, Rectal, Rectal Tumors, Rectum Cancer, Rectum Neoplasms | 05/25 | 05/26 | | |
| Recruiting | N/A | 5000 | RoW | Blood test | Wuhan Union Hospital, China | Neoplasms, Cancer | 11/24 | 12/24 | | |
| Recruiting | N/A | 48 | RoW | Carbon ion radiotherapy | Shanghai Proton and Heavy Ion Center | Pancreatic Cancer Non-resectable | 12/25 | 12/26 | | |
| Not yet recruiting | N/A | 100 | RoW | Molecular Profiling & drug testing in tumor organoids and PDXs | Wuhan Union Hospital, China | Advanced Colorectal Carcinoma, Recurrent Colorectal Carcinoma | 07/26 | 07/26 | | |
| Tan, Lijie |
POINT, NCT04513418: Effects of Preoperative Enteral Immunonutrition for Esophageal Cancer Patients Given Neoadjuvant Chemoradiotherapy |
|
|
| Recruiting | 3 | 244 | RoW | Preoperative immunonutrition | Hecheng Li M.D., Ph.D, Shanghai Chest Hospital, Shanghai Zhongshan Hospital, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Ningbo Medical Center Lihuili Hospital, Zhejiang Cancer Hospital, Fujian Medical University Union Hospital, Shanghai East Hospital | Esophageal Neoplasms | 03/25 | 12/28 | | |
| Recruiting | 3 | 360 | RoW | esophagectomy, minimally invasive esophagectomy | Shanghai Chest Hospital, Ruijin Hospital, Changhai Hospital, Shanghai Zhongshan Hospital, The First Affiliated Hospital of Nanchang University | Esophageal Cancer, Esophageal Carcinoma | 12/24 | 12/24 | | |
NCT05043688: Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC. |
|
|
| Recruiting | 3 | 426 | RoW | Camrelizumab, radiotherapy | Zhigang Li, Jiangsu HengRui Medicine Co., Ltd. | Resectable Esophageal Squamous Cell Carcinoma | 12/28 | 12/30 | | |
NCT04848753: Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma |
|
|
| Active, not recruiting | 3 | 663 | RoW | Toripalimab combined with cisplatin and paclitaxel, Placebo combined with cisplatin and paclitaxel | Shanghai Junshi Bioscience Co., Ltd. | Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | 05/27 | 05/27 | | |
NCT04973306: Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC |
|
|
| Recruiting | 2/3 | 176 | RoW | Neoadjuvant Chemoradiotherapy, Tislelizumab, anti-PD-1 antibody, Ivor-Lewis or Mckeown Esophagectomy(Mckeown Esophagectomy recommended) | Shanghai Zhongshan Hospital, Beijing Cancer Hospital, Shanghai Chest Hospital, First Affiliated Hospital of Wenzhou Medical University, Tianjin Medical University Cancer Institute and Hospital, Ningbo Medical Center Lihuili Hospital, The First People's Hospital of Changzhou, Zhongshan Hospital, Fudan University (Xiamen Branch), Xuhui Central Hospital, Shanghai, Shanghai Minhang Central Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Zhejiang Cancer Hospital, Sichuan Cancer Hospital and Research Institute, Tongji Hospital, Sun Yat-sen University, Shanghai Fifth People's Hospital | Esophageal Squamous Cell Carcinoma Stage II, Esophageal Squamous Cell Carcinoma Stage III | 07/24 | 07/27 | | |
